Effects of SR141716A on cognitive and depression-related behavior in an animal model of premotor Parkinson's disease

Parkinson's Disease

Volumn , Issue , 2010, Pages

  Takahashi, R N ^a   Tadaiesky, M T ^a   Dombrowski, P A ^b   Da Cunha, C ^b  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^b FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID 1 RECEPTOR; MONOAMINE; OXIDOPAMINE; RIMONABANT;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; COGNITION; COGNITIVE DEFECT; CORPUS STRIATUM; DEPRESSION; DOPAMINERGIC NERVE CELL; DRUG EFFECT; EMOTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; NERVE DEGENERATION; NONHUMAN; PARKINSON DISEASE; PREFRONTAL CORTEX; PREMOTOR CORTEX; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; RECOGNITION; TASK PERFORMANCE;

EID: 78349258617     PISSN: None     EISSN: 20420080     Source Type: Journal    
DOI: 10.4061/2010/238491     Document Type: Article

References (29)

1. Tolosa E., Poewe W., Premotor Parkinson disease Neurology 2009 72 7 S1
2. Becker G., Mller A., Braune S., Bttner T., Benecke R., Greulich W., Klein W., Mark G., Rieke J., Thmler R., Early diagnosis of Parkinson's disease Journal of Neurology, Supplement 2002 249 3 40 48
3. Tissingh G., Bergmans P., Booij J., Winogrodzka A., van Royen E. A., Stoof J. C., Wolters E. C., Drug-naive patients with Parkinson's disease in Hoehn and Yahr stages I and II show a bilateral decrease in striatal dopamine transporters as revealed by [123I] -CIT SPECT Journal of Neurology 1998 245 1 14 20
4. Tadaiesky M. T., Dombrowski P. A., Figueiredo C. P., Cargnin-Ferreira E., Da Cunha C., Takahashi R. N., Emotional, cognitive and neurochemical alterations in a premotor stage model of Parkinson's disease Neuroscience 2008 156 4 830 840
5. Lutz B., Endocannabinoid signals in the control of emotion Current Opinion in Pharmacology 2009 9 1 46 52
6. Wotjak C. T., Role of endogenous cannabinoids in cognition and emotionality Mini-Reviews in Medicinal Chemistry 2005 5 7 659 670
7. Piomelli D., The molecular logic of endocannabinoid signalling Nature Reviews Neuroscience 2003 4 11 873 884
8. Pisani A., Fezza F., Galati S., Battista N., Napolitano S., Finazzi-Agr A., Bernardi G., Brusa L., Pierantozzi M., Stanzione P., Maccarrone M., High endogenous cannabinoid levels in the cerebrospinal fluid of untreated Parkinson's disease patients Annals of Neurology 2005 57 5 777 779
9. Di Marzo V., Hill M. P., Bisogno T., Crossman A. R., Brotchie J. M., Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease FASEB Journal 2000 14 10 1432 1438
10. Gubellini P., Picconi B., Bari M., Battista N., Calabresi P., Centonze D., Bernardi G., Finazzi-Agr A., Maccarrone M., Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission Journal of Neuroscience 2002 22 16 6900 6907
11. Fernandez-Espejo E., Caraballo I., de Fonseca F. R., El Banoua F., Ferrer B., Flores J. A., Galan-Rodriguez B., Cannabinoid CB1 antagonists possess antiparkinsonian efficacy only in rats with very severe nigral lesion in experimental parkinsonism Neurobiology of Disease 2005 18 3 591 601
12. Gonzlez S., Scorticati C., Garca-Arencibia M., de Miguel R., Ramos J. A., Fernndez-Ruiz J., Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson's disease Brain Research 2006 1073-1074 1 209 219
13. van der Stelt M., Fox S. H., Hill M., Crossman A. R., Petrosino S., Di Marzo V., Brotchie J. M., A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease FASEB Journal 2005 19 9 1140 1142
14. Cao X., Liang L., Hadcock J. R., Iredale P. A., Griffith D. A., Menniti F. S., Factor S., Greenamyre J. T., Papa S. M., Blockade of cannabinoid type 1 receptors augments the antiparkinsonian action of levodopa without affecting dyskinesias in 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-treated rhesus monkeys Journal of Pharmacology and Experimental Therapeutics 2007 323 1 318 326
15. Mackie K., Distribution of cannabinoid receptors in the central and peripheral nervous system Handbook of Experimental Pharmacology 2005 168 299 325
16. Paxinos G., Watson C., The Rat Brain in Stereotaxic Coordinates 2005 5th San Diego, Calif, USA Academic Press
17. Porsolt R. D., Anton G., Blavet N., Jalfre M., Behavioural despair in rats: a new model sensitive to antidepressant treatments European Journal of Pharmacology 1978 47 4 379 391
18. Prediger R. D. S., Takahashi R. N., Ethanol improves short-term social memory in rats. Involvement of opioid and muscarinic receptors European Journal of Pharmacology 2003 462 13 115 123
19. Griebel G., Stemmelin J., Scatton B., Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents Biological Psychiatry 2005 57 3 261 267
20. Shearman L. P., Rosko K. M., Fleischer R., Wang J., Xu S., Tong X. S., Rocha B. A., Antidepressant-like and anorectic effects of the cannabinoid CB1 receptor inverse agonist AM251 in mice Behavioural Pharmacology 2003 14 8 573 582
21. Tzavara E. T., Davis R. J., Perry K. W., Li X., Salhoff C., Bymaster F. P., Witkin J. M., Nomikos G. G., The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions British Journal of Pharmacology 2003 138 4 544 553
22. Herkenham M., Lynn A. B., de Costa B. R., Richfield E. K., Neuronal localization of cannabinoid receptors in the basal ganglia of the rat Brain Research 1991 547 2 267 274
23. Meltzer H. Y., Arvanitis L., Bauer D., Rein W., Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder American Journal of Psychiatry 2004 161 6 975 984
24. Hampson R. E., Deadwyler S. A., Cannabinoids, hippocampal function and memory Life Sciences 1999 65 6-7 715 723
25. Lutz B., The endocannabinoid system and extinction learning Molecular Neurobiology 2007 36 1 92 101
26. Deadwyler S. A., Goonawardena A. V., Hampson R. E., Short-term memory is modulated by the spontaneous release of endocannabinoids: evidence from hippocampal population codes Behavioural Pharmacology 2007 18 5-6 571 580
27. Micale V., Cristino L., Tamburella A., Petrosino S., Leggio G. M., Di Marzo V., Drago F., Enhanced cognitive performance of dopamine D3 receptor " knock-out" mice in the step-through passive-avoidance test: assessing the role of the endocannabinoid/endovanilloid systems Pharmacological Research 2010 61 6 531 536
28. Terranova J.-P., Storme J.-J., Lafon N., Prio A., Rinaldi-Carmona M., Le Fur G., Soubri P., Improvement of memory in rodents by the selective GB1 cannabinoid receptor antagonist, SR 141716 Psychopharmacology 1996 126 2 165 172
29. Brotchie J. M., CB1 cannabinoid receptor signalling in Parkinson's disease Current Opinion in Pharmacology 2003 3 1 54 61